Veerhealth Care's Q2 FY27 saw revenue skyrocket 461% year-on-year to ₹22.35 crore, though it slipped 10% from the prior quarter. Profit remained resilient at ₹1.21 crore, supported by a robust order book and contract manufacturing deals.
For Veerhealth Care, the September quarter was about scaling from a micro-cap base into a serious contract manufacturer. The company's explosive growth, driven by long-term deals with top FMCG players and US exports, has fundamentally changed its revenue profile in just a year.
The numbers show a business in rapid transition. Revenue for Q2 FY27 stood at ₹22.35 crore, a staggering 461% jump from the ₹3.98 crore reported in the same quarter last year. Net profit followed suit, rising 384% year-on-year to ₹1.21 crore. Sequentially, revenue moderated, dipping 10% from Q1's ₹24.93 crore, while profit held nearly flat, declining just 1.6%.
Revenue & profit
Revenue (₹ Cr)
Profit (₹ Cr)
Revenue (₹ Cr), Q2 FY26: 3.98
Revenue (₹ Cr), Q3 FY26: 7.26
Revenue (₹ Cr), Q4 FY26: 16.76
Revenue (₹ Cr), Q1 FY27: 24.93
Revenue (₹ Cr), Q2 FY27: 22.35
Profit (₹ Cr), Q2 FY26: 0.25
Profit (₹ Cr), Q3 FY26: 0.41
Profit (₹ Cr), Q4 FY26: -0.35
Profit (₹ Cr), Q1 FY27: 1.23
Profit (₹ Cr), Q2 FY27: 1.21
Revenue (₹ Cr)
Revenue (₹ Cr), Q2 FY26: 3.98
Revenue (₹ Cr), Q3 FY26: 7.26
Revenue (₹ Cr), Q4 FY26: 16.76
Revenue (₹ Cr), Q1 FY27: 24.93
Revenue (₹ Cr), Q2 FY27: 22.35
Profit (₹ Cr)
Profit (₹ Cr), Q2 FY26: 0.25
Profit (₹ Cr), Q3 FY26: 0.41
Profit (₹ Cr), Q4 FY26: -0.35
Profit (₹ Cr), Q1 FY27: 1.23
Profit (₹ Cr), Q2 FY27: 1.21
Net Profit Margin
Net Profit Margin, Q2 FY26: 6.3%
Net Profit Margin, Q3 FY26: 5.6%
Net Profit Margin, Q4 FY26: -2.1%
Net Profit Margin, Q1 FY27: 4.9%
Net Profit Margin, Q2 FY27: 5.4%
Metric
CurrentQ2 FY27
PreviousQ1 FY27
Same quarter LYQ2 FY26
Revenue (₹ Cr)
22.35YoY +462%
24.93
3.98
Profit (₹ Cr)
1.21YoY +384%
1.23
0.25
Net Profit Margin
5.4%YoY -14%
4.9%
6.3%
The Engine Behind the Surge
Management, in an investor call detailed by MCapital, attributed the year-on-year leap to a strategic pivot. Contract manufacturing for a leading Indian FMCG company now drives about 70% of sales, with US institutional toothpaste exports contributing 20%. This shift from a small own-brand business explains the massive percentage gains from a low base.
The sequential dip in revenue, according to a company statement cited by News Tulsian, was partly due to geopolitical tensions delaying some export dispatches in Q2. These shipments have since resumed. The underlying demand appears strong, with the company announcing a series of orders through FY27, including a ₹4.55 crore repeat order from an FMCG major.
Costs Catch Up with Scale
While revenue multiplied, expenses grew in tandem. Total expenses rose 445% year-on-year. Employee costs increased 15% sequentially, which MarketsMojo notes reflects investment in human capital for expansion. The net profit margin contracted 90 basis points compared to Q2 FY26, settling at 5.4%.
Live Chart
· VEERHEALTH
(BSE)
ISIN: INE882C01035
This margin pressure highlights the trade-off in a high-growth phase: volume expansion is prioritized over immediate profitability optimization. The company's operating cash flow turned negative (₹-1.63 crore for H1), as reported by MarketPing, as working capital needs surged with higher inventory to support the sales ramp-up.
A Full Year Already in the Bag
The most telling figure isn't in the quarterly table. As noted by MCapital, the company's first-half revenue of ₹47.28 crore has already surpassed the entire previous fiscal year's turnover of ₹32.48 crore. This sets the stage for management's ambitious full-year guidance of approximately ₹100 crore in revenue and ₹5-6 crore in PAT for FY27.
Execution of a planned capacity expansion is critical. Management guidance, reported by Sovrenn, targets increasing production area from 60,000 to 90,000 sq ft by December 2026, adding new manufacturing lines to meet demand.
Key Points
Revenue grew over 460% year-on-year, propelled by contract manufacturing deals constituting 70% of sales.
Profitability held steady quarter-on-quarter despite a 10% sequential revenue dip, with margins showing modest sequential improvement.
First-half FY27 revenue has already exceeded full-year FY26 sales, underpinning an aggressive full-year guidance of ~₹100 crore turnover.
The expansion is capital-intensive, reflected in negative operating cash flow and rising employee and working capital costs.
“
Hexa Perspective
Veerhealth Care's story is no longer about incremental growth but a complete business model transformation. The validation from large, repeat FMCG contracts provides visibility, but it also ties the company's fortunes to a handful of large customers and their inventory cycles.
The next few quarters will test the durability of this new scale. Investors are weighing the explosive top-line growth against thin margins and the cash consumed to achieve it. The stock's 195% one-year return suggests the market is betting on the guidance, but the path to sustained, profitable scale remains the key hurdle.
Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.
Frequently asked questions
What were Veerhealth Care's Q2 FY27 results?
Veerhealth Care reported Q2 FY27 (September 2026) revenue of ₹22.35 crore, a 461% increase year-on-year. Net profit for the quarter was ₹1.21 crore, up 384% from the same period last year. Sequentially, revenue declined 10% from Q1 FY27, while profit dipped slightly by 1.6%.
What drove Veerhealth Care's massive revenue growth in Q2 FY27?
The explosive 461% year-on-year growth was driven by a strategic shift into contract manufacturing. Management stated, per MCapital, that deals with a top Indian FMCG company now constitute about 70% of revenue, supplemented by 20% from US institutional toothpaste exports.
Why did Veerhealth Care's revenue decline from Q1 to Q2 FY27?
Revenue declined 10% sequentially from ₹24.93 crore in Q1 to ₹22.35 crore in Q2 FY27. The company cited geopolitical tensions delaying some export dispatches during the quarter, as reported by News Tulsian, though these shipments have since resumed.
What is Veerhealth Care's guidance for FY27?
Veerhealth Care management has guided for approximately ₹100 crore in total revenue and a net profit (PAT) of ₹5-6 crore for the full financial year 2026-27. This outlook was shared in an investor call, as reported by MCapital and Sovrenn.
What is Veerhealth Care's order book status?
While a formal order book is not disclosed, the company has announced several significant orders in FY27. These include repeat orders from a leading FMCG company, such as a ₹4.55 crore skincare order, and export contracts, providing a pipeline to support its ₹100 crore revenue guidance.
What are Veerhealth Care's capacity expansion plans?
Veerhealth Care plans to expand its production area from 60,000 square feet to 90,000 square feet by December 2026. This expansion, noted in a concall summary by Sovrenn, includes adding new manufacturing lines to support the growth from FMCG contracts and export orders.
What was Veerhealth Care's net profit margin in Q2 FY27?
Veerhealth Care's net profit margin (PAT margin) was 5.4% in Q2 FY27. This represents a 90 basis point contraction from the 6.3% margin in Q2 FY26, as costs rose with rapid business expansion, but a 50 basis point improvement from the 4.9% margin in Q1 FY27.
How did Veerhealth Care's cash flow perform in H1 FY27?
Operating cash flow was negative at ₹-1.63 crore for the first half of FY27, as reported by MarketPing. This was due to a significant increase in inventory and working capital requirements to support the surge in revenue, despite the company reporting a profit.
What is Veerhealth Care's shareholding pattern?
As of September 2026, promoter holding stood at 31.88%, with the remaining 68.12% held by non-institutional investors, primarily retail. MarketsMojo notes a complete absence of institutional investors (FIIs, mutual funds), which is common for micro-cap companies.
Did Veerhealth Care's Q2 results beat estimates?
Specific analyst estimates are not cited, but the company's H1 FY27 revenue of ₹47.28 crore has already exceeded its full-year FY26 revenue of ₹32.48 crore. An analysis by MCapital viewed this as a very positive outcome, implying the company is tracking well ahead of its previous run-rate.
Veerhealth Care Q2 FY27 results August 2026
Veerhealth Care's Q2 FY27 results for the period ending September 2026 were announced on November 14, 2026. The company reported revenue of ₹22.35 crore and a net profit of ₹1.21 crore, marking massive year-on-year growth driven by new contract manufacturing deals.
Veerhealth Care H1FY27 revenue
Veerhealth Care's standalone revenue for the first half of FY27 (H1FY27) was ₹47.28 crore, as reported by MarketPing and News Tulsian. This represents a 458% increase year-on-year and already surpasses the company's full-year revenue for FY26, which was ₹32.48 crore.